Standout Papers
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (2017)
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial (2018)
Immediate Impact
6 by Nobel laureates 17 from Science/Nature 64 standout
Citing Papers
Natural killer cell therapies
2024 StandoutNature
Refining the impact of genetic evidence on clinical success
2024 StandoutNature
Works of Thomas Olencki being referenced
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)
2015
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
1998
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Thomas Olencki | 1991 | 1701 | 1515 | 120 | 3.8k | |
| Leonard J. Appleman | 1481 | 1157 | 1304 | 176 | 3.3k | |
| Hiroyuki Katoh | 1723 | 1428 | 1361 | 162 | 4.5k | |
| Jens Atzpodien | 2178 | 1342 | 1299 | 140 | 3.9k | |
| Erminia Massarelli | 3100 | 2060 | 1208 | 139 | 4.5k | |
| Samra Turajlic | 2347 | 1333 | 2194 | 90 | 4.7k | |
| Luana Calabrò | 2222 | 1464 | 1405 | 110 | 4.3k | |
| Salvador Martín‐Algarra | 2212 | 906 | 1319 | 141 | 3.8k | |
| Julien Adam | 2919 | 1584 | 1099 | 169 | 4.6k | |
| Dimitrios Bafaloukos | 2958 | 1569 | 1208 | 129 | 4.4k | |
| Chao Zhao | 2203 | 1936 | 1123 | 130 | 3.6k |
All Works
Loading papers...